



31st May 2020

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Subject: Submission of Disclosure on Related Party Transactions

In Compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, - we hereby submit the attached Related Party Transactions, on consolidated basis, drawn in accordance with applicable accounting standards for period ended 31st March 2020.

Thanking you,

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

AJAY AVINASH NADKARNI
Digitally signed by AJAY
AVINASH NADKARNI
Date: 2020.05.31
12:54:06 +05'30'

Ajay Nadkarni
Vice President – Administration,
Real Estate & Company Secretary

Pursuant to Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

1 Relationships (during the year):

(i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company :

Glaxo Group Limited, U.K.
GlaxoSmithKline Pte Limited, Singapore
Eskaylab Limited, U.K.
Burroughs Wellcome International Limited, U.K.

Holding company / ultimate holding company of the above shareholders

GlaxoSmithKline Plc, U.K. *
GlaxoSmithKline Finance Plc, U.K.*
Setfirst Ltd, U.K. *
SmithKline Beecham Limited, U.K.
Wellcome Limited, U.K.*
The Wellcome Foundation Limited, U.K.*
Wellcome Consumer Healthcare Limited, U.K.*

* no transactions during the year

(ii) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the year:

GlaxoSmithKline Asia Private Limited, India
GlaxoSmithKline Brasil Ltda, Brazil*
GlaxoSmithKline Consumer Healthcare Limited, India
GlaxoSmithKline Biologicals S.A., Belgium
GlaxoSmithKline Pharmaceuticals S.A., Belgium
GlaxoSmithKline Services Unlimited, U.K.
Glaxo Operations UK Limited, U.K
GlaxoSmithKline Export Limited, U.K.
GlaxoSmithKline Latin America S.A*
GlaxoSmithKline Pakistan Limited, Pakistan*
GlaxoSmithKline Research & Development Ltd, U.K
GlaxoSmithKline Pte Limited, Singapore
GlaxoSmithKline Corporate Centre, U.S.A*
GlaxoSmithKline Philippines Inc., Philippines*
GlaxoSmithKline Australia Pty Limited, Australia*
GlaxoSmithKline Trading Services Limited, Ireland
GlaxoSmithKline Limited, Hong Kong*
GlaxoSmithKline South Africa (Pty) Ltd, South Africa*
GlaxoSmithKline LLC, U.S.A*
GlaxoSmithKline Pharmaceutical Nigeria Limited, Nigeria
Stiefel India Private Limited, India
Glaxo Wellcome Ceylon Ltd., Sri Lanka*
GlaxoSmithKline Pharmaceutical Ltd., Sri Lanka
ViiV Healthcare Limited, UK
US GMS Financial Services, U.S.A.*
GlaxoSmithKline Inc, Philadelphia*
GlaxoSmithKline Manufacturing SPA, Italy*
GlaxoSmithKline Intellectual Property Limited*

* no transactions during the year

(iii) Directors and members of GSK India Leadership Team :

Directors:

Mr. A. Vaidheesh # (upto March 31, 2020)
Ms. P. Thakur #
Mr. R. Krishnaswamy #
Mr. N. Kaviratne
Mr. P. Bhide
Ms. R.S. Karnad (w.e.f. April 1, 2019)
Mr. A.N. Roy
Mr. D. Sundaram
Mr. S. Williams
Ms. A. Bansal (upto March 29, 2020)
Mr. D.S. Parekh (upto March 31, 2019)
Mr. R.R. Bajaj (upto July 24, 2018)
Mr. M.Jones (upto July 24, 2018)

GSK India Leadership Team:

Mr. A. Nadkarni
Mr. R. D'souza
Mr. S. Dheri
Ms. S. Choudhary
Mr. B. Kotak
Mr. A. Iyer
Ms. M. Priyam
Ms. D. Jakate
Ms. S. Zota (w.e.f March 23, 2020)
Mr. N. Hindia (w.e.f. June 01, 2018 upto March 22, 2020)
Mr. G. Kotian (w.e.f. October 01, 2018 upto October 31, 2019)
Mr. N. Sudrik (w.e.f. October 01, 2018 upto October 31, 2019)
Mr. S. Webb (w.e.f. January 17, 2018 upto January 31, 2019)
Mr. S. Balasubramanian (w.e.f. October 01, 2018)
Mr. V. Balakrishnan (upto September 21, 2018)
Mr. R. Bartaria (upto August 31, 2018)
Mr. K. Hazari (upto May 31, 2018)

Also member of GSK India Leadership Team

Related Party disclosures (continued)

2 The following transactions were carried out with the related parties in the ordinary course of business:

(i) Dividend paid to parties referred to in item 1(i) above:

	(Rupees in lakhs) Year ended March 31, 2020
Glaxo Group Limited, U.K.	121,94.10
GlaxoSmithKline Pte Limited, Singapore	95,20.80
Eskaylab Limited, U.K.	23,52.00
Burroughs Wellcome International Limited, U.K.	13,44.00

(ii) Details relating to parties referred to in items 1(i) and 1(ii) above:

(Rupees in lakhs)

	Holding company/ultimate holding company 1(i) Year ended March 31, 2020	Other companies in the GSK Group 1(ii) Year ended March 31, 2020
1 Purchase of materials/traded goods	-	634,52.35
2 Sale of materials/sale of products	-	23.92
3 Purchase of Intangible assets	-	-
4 Sale of laptops	-	28.56
5 Expenses recharged to other companies	36.05	27,93.64
6 Expenses recharged by other companies	-	74,67.46
7 Manufacturing charges recovered	-	13,84.54
8 Clinical research and data management recoveries	-	8,98.26
9 Liabilities written back	-	-
10 Employee benefit liabilities transferred to a related party	-	13.51
11 Outstanding receivables at the period end	-	7,30.82
12 Outstanding payables at the period end	-	56,77.24
13 Cross Charges Recoverable at the period end	-	1,25.22

Note : Transactions and balances with its own subsidiary are eliminated upon consolidation.

(iii) Details relating to persons referred to in item 1(iii) above:

(Rupees in lakhs)

	Year ended March 31, 2020
1 Remuneration/commission/sitting fees	40,91.89
2 Payments under the long-term incentive plan	5,16.49

Pursuant to Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

1 Relationships (during the year):

(i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company :

Glaxo Group Limited, U.K.
GlaxoSmithKline Pte Limited, Singapore
Eskaylab Limited, U.K.
Burroughs Wellcome International Limited, U.K.

Holding company / ultimate holding company of the above shareholders

GlaxoSmithKline Plc, U.K. *
GlaxoSmithKline Finance Plc, U.K. *
Setfirst Ltd, U.K. *
SmithKline Beecham Limited, U.K.
Wellcome Limited, U.K. *
The Wellcome Foundation Limited, U.K. *
Wellcome Consumer Healthcare Limited, U.K. *

* no transactions during the year

(ii) Subsidiary of the Company :

Biddle Sawyer Limited, a wholly owned subsidiary of the Company

(iii) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the year:

GlaxoSmithKline Asia Private Limited, India
GlaxoSmithKline Brasil Ltda, Brazil*
GlaxoSmithKline Consumer Healthcare Limited, India
GlaxoSmithKline Biologicals S.A., Belgium
GlaxoSmithKline Pharmaceuticals S.A., Belgium
GlaxoSmithKline Services Unlimited, U.K.
Glaxo Operations UK Limited, U.K.
GlaxoSmithKline Export Limited, U.K.
GlaxoSmithKline Latin America S.A.*
GlaxoSmithKline Pakistan Limited, Pakistan*
GlaxoSmithKline Research & Development Ltd, U.K.
GlaxoSmithKline Pte Limited, Singapore
GlaxoSmithKline Corporate Centre, U.S.A.*
GlaxoSmithKline Philippines Inc., Philippines*
GlaxoSmithKline Australia Pty Limited, Australia*
GlaxoSmithKline Trading Services Limited, Ireland
GlaxoSmithKline Limited, Hong Kong*
GlaxoSmithKline South Africa (Pty) Ltd, South Africa*
GlaxoSmithKline LLC, U.S.A.*
GlaxoSmithKline Pharmaceutical Nigeria Limited, Nigeria
Stiefel India Private Limited, India
Glaxo Wellcome Ceylon Ltd., Sri Lanka*
GlaxoSmithKline Pharmaceutical Ltd., Sri Lanka
ViiV Healthcare Limited, UK
US GMS Financial Services, U.S.A. *
GlaxoSmithKline Inc, Philadelphia*
GlaxoSmithKline Manufacturing SPA, Italy*
GlaxoSmithKline Intellectual Property Limited*

* no transactions during the year

(iv) Directors and members of GSK India Leadership Team :

Directors:

Mr. A. Vaidheesh # (upto March 31, 2020)
Ms. P. Thakur #
Mr. R. Krishnaswamy #
Mr. N. Kaviratne
Mr. P. Bhide
Ms. R. S. Karnad (w.e.f. April 1, 2019)
Mr. A.N. Roy
Mr. D. Sundaram
Mr. S. Williams
Mr. R.R. Bajaaj (upto July 24, 2018)
Mr. D.S. Parekh (upto March 31, 2019)
Ms. A. Bansal (upto March 29, 2020)
Mr. M.Jones (upto July 24, 2018)

GSK India Leadership Team:

Mr. A. Nadkarni
Mr. R. D'souza
Mr. S. Dheri
Ms. S. Choudhary
Mr. B. Kotak
Mr. A. Iyer
Ms. M. Priyam
Ms. D. Jakate
Mr. S. Webb (w.e.f. January 17, 2018 upto January 31, 2019)
Mr. V. Balakrishnan (upto September 21, 2018)
Mr. S. Balasubramanian (w.e.f. October 01, 2018)
Mr. N. Hindia (w.e.f. June 01, 2018 upto March 22, 2020)
Mr. G. Kotian (w.e.f. October 01, 2018 upto October 31, 2019)
Mr. N. Sudrik (w.e.f. October 01, 2018 upto October 31, 2019)
Ms. S. Zota (w.e.f. March 23, 2020)
Mr. R. Bartaria (upto August 31, 2018)
Mr. K. Hazari (upto May 31, 2018)

Also member of GSK India Leadership Team

2 The following transactions were carried out with the related parties in the ordinary course of business:

(i) Dividend paid to parties referred to in item 1(i) above:

(Rupees in lakhs)

	Year ended March 31, 2020
Glaxo Group Limited, U.K.	121,94.10
GlaxoSmithKline Pte Limited, Singapore	95,20.80
Eskaylab Limited, U.K.	23,52.00
Burroughs Wellcome International Limited, U.K.	13,44.00

Related Party disclosures (continued)

(ii) Details relating to parties referred to in items 1(i), 1(ii) and 1(iii) above:

(Rupees in lakhs)

	Holding company/ultimate holding company 1(i)	Subsidiary of the company 1(ii)	Other companies in the GSK Group 1(iii)
	Year ended March 31, 2020	Year ended March 31, 2020	Year ended March 31, 2020
1 Purchase of materials/traded goods	-	-	634,52.35
2 Sale of materials/sale of products	-	-	23.92
3 Purchase of Intangible assets	-	-	-
4 Sale of laptops	-	-	28.56
5 Expenses recharged to other companies	36.05	35.34	27,93.64
6 Expenses recharged by other companies	-	-	74,67.46
7 Manufacturing charges recovered	-	-	13,84.54
8 Clinical research and data management recoveries	-	-	8,98.26
9 Liabilities written back	-	-	-
10 Employee benefit liabilities transferred to a related party	-	-	13.51
11 Outstanding receivables at the period end	-	-	7,30.82
12 Outstanding payables at the period end	-	35.58	56,77.24
13 Cross charges recoverable at the period end	-	-	1,25.22

(iii) Details relating to persons referred to in item 1(iv) above:

(Rupees in lakhs)

	Year ended March 31, 2020
1 Remuneration/commission/sitting fees	40,91.89
2 Payments under the long-term incentive plan	5,16.49